Norifaz (Risedronate Sodium)

Risedronate Sodium, the active ingredient in Norifaz, is a bisphosphonate presented as an oral formulation for oral use. It is indicated for the treatment of osteoporosis in postmenopausal women and men, as well as for Paget's disease of bone.

GNH USA supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides reliable sourcing for regulated markets through established distribution networks and comprehensive regulatory support for importers.

Norifaz (risedronate sodium) is used to manage bone‑remodeling disorders by reducing excessive bone loss.

Osteoporosis in postmenopausal women: reduces bone resorption, leading to increased bone mineral density and a lower risk of vertebral and non‑vertebral fractures. Osteoporosis in men: enhances bone strength by inhibiting osteoclast activity, thereby improving bone mineral density and decreasing fracture rates. Paget's disease of bone: suppresses abnormal osteoclastic activity, helping to normalize bone remodeling, reduce bone pain, and improve skeletal architecture.

Risedronate sodium may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal pain: mild discomfort in the stomach area. - Nausea: feeling of queasiness often without vomiting. - Dyspepsia: indigestion with bloating or heartburn. - Constipation: difficulty passing stools. - Flatulence: excess gas in the gastrointestinal tract. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the mouth that fails to heal. - Atypical femur fracture: unusual break in the thigh bone with minimal trauma. - Severe esophageal irritation: ulceration or inflammation causing pain on swallowing. - Acute hypocalcemia: markedly low blood calcium levels requiring medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Before initiating therapy with Norifaz, several precautionary measures should be considered to ensure safe use.

Assess renal function: avoid use in patients with severe renal impairment (creatinine clearance <30 mL/min). Ensure adequate calcium and vitamin D intake: supplement as needed to maintain normal serum levels. Take with a full glass of water: remain upright for at least 30 minutes to reduce esophageal irritation. Avoid concomitant use of NSAIDs or corticosteroids: these may increase gastrointestinal risk. Monitor serum calcium: check levels periodically, especially in patients with risk factors for hypocalcemia. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Risedronate sodium can interact with other medicines, affecting its absorption or increasing the risk of adverse effects.

Major Interactions (Avoid): - Concurrent use with other bisphosphonates: may amplify bone toxicity. - Co‑administration with calcium, iron, or multivitamin supplements within 2 hours: markedly reduces risedronate absorption. - Use with NSAIDs or corticosteroids: heightened risk of gastrointestinal irritation or ulceration. - Combination with drugs causing hypocalcemia (e.g., loop diuretics): may exacerbate low calcium levels.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may lower drug bioavailability; separate dosing by at least 30 minutes. - Proton pump inhibitors: altered gastric pH can affect absorption. - Warfarin: potential increase in INR and bleeding risk; monitor coagulation parameters. - Thiazide diuretics: may affect calcium balance; observe serum electrolytes.